On Tuesday, Shares of Arrowhead Research Corp (NASDAQ:ARWR), lost -1.14% to $5.19.
Arrowhead Research Corporation, declared that additional clinical data on ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B infection, will be presented in the late-breaking poster session at The Liver Meeting 2015, the 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 13-17, 2015, in San Francisco.
The late-breaking abstract details results from the Heparc-2001, Phase 2 study of ARC-520 in combination with entecavir (ETV). Key findings comprise the following:
- Naïve patients reduced viral DNA up to 4.3 log (mean 2.2 log)
- Naïve e-antigen (HBeAg) positive patients reduced surface antigen (HBsAg) up to 1.9 log (mean max 1.1 log)
- ARC-520 reduced HBeAg up to 1.7 log (mean max 1.2 log)
- ARC-520 therapy was well tolerated with no adverse events rated serious, severe, drug-related or causing withdrawal from the trial
- 15 patients are ongoing in follow-up and additional results may be available to report at The Liver Meeting
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
Shares of Canadian Solar Inc. (NASDAQ:CSIQ), declined -0.41% to $21.65, during its last trading session.
Canadian Solar Inc., declared that it started the commercial operation of four solar photovoltaic (PV) power plants in Japan, totaling about 8.6 MWp.
The 8.6 MWp portfolio of projects comprise the 2.6 MWp Hijimachi Fujiwara solar power plant in Hayami-gun, Oita Prefecture, the 2.2 MWp Koba solar power plant in Isa-shi City, Kagoshima Prefecture, the 2.1 MWp Tsukuba Holes solar power plant in Kasama-shi City, Ibaraki Prefecture and the 1.7 MWp Yusuicho solar power plant in Aira-gun, Kagoshima Prefecture.
Financing for these four projects is being offered by Rabobank Hong Kong, following a credit agreement declared on July 28, 2015. As formerly revealed, the credit facility has a two-year maturity and will be used to finance the construction of an initial portfolio of up to 20 MWp of the Company’s solar power plants in Japan.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar power products worldwide. The company operates in two segments, Module and Energy. Its products comprise various solar modules that are used in residential, commercial, and industrial solar power generation systems.
Finally, Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), ended its last trade with -1.01% loss, and closed at $7.86.
Achillion Pharmaceuticals, declared that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) has initiated treatment in a phase 2a clinical trial to evaluate the safety, pharmacokinetics and efficacy of AL-335, odalasvir (also known as ACH-3102), and simeprevir in treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection.
This phase 2a study is a randomized, open-label, three-arm study of AL-335, a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir, an HCV NS5A inhibitor, and simeprevir, an HCV NS3/4A protease inhibitor. Patients will be randomized to one of three treatment arms and receive once daily treatment for a duration of four, six or eight weeks. The primary objective of the study is to establish the safety of the treatment regimen with secondary endpoints compriseing of pharmacokinetics, the proportion of subjects achieving sustained viral response (SVR), and the effect on the viral resistance profile after treatment. The study is predictable to enroll about 60 patients across the three treatment arms.
As formerly declared on May 19, 2015, Achillion has granted Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion’s HCV assets which comprise odalasvir (ACH-3102), ACH-3422, and sovaprevir.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
